Summary. Bruton's tyrosine kinase (Btk) is a non-receptor protein tyrosine kinase (PTK) that is expressed in all haemopoietic lineages except mature T cells and plasma cells. Despite the broad range of expression, mutations that inactivate this molecule affect primarily the development of the B-cell lineage. As a PTK, Btk could potentially be involved directly or indirectly in the processes that relate to the malignant transformation of all the cell lineages where this molecule is expressed. Previous studies have failed to demonstrate mutations in patients with B-cell origin acute lymphoblastic leukaemia (ALL).
lineages with the exception of mature T lymphocytes and plasma cells (Smith et al, 1994) . Despite the broad expression pattern, mutations that inactivate the Btk gene or the Btk protein, both in man and in mouse experimental models, appear to affect primarily the B-cell lineage (Vetrie et al, 1993; Tsukada et al, 1993; Thomas et al, 1993; Rawlings et al, 1993) .
Btk belongs to the Src superfamily of tyrosine kinases and contains the Src characteristic homology domains, SH3, SH2 and kinase domain (SH1) (Bolen, 1993; Pawson, 1997) . On the basis of sequence homology, Btk, together with the most related kinases Tec and Itc, constitute a distinct subfamily (Mano et al, 1993; Siliciano et al, 1992; Sato et al, 1994) . The members of the Tec/Btk subfamily, in addition to the SH1, SH2 and SH3 domains, and instead of the SH4 domain of the Src kinases, contain at the N-terminus a pleckstrin homology (PH) domain which might be involved in the recruitment of the kinases to the cell membrane, followed by the Tec homology (TH) domain that contains a proline-rich sequence (PR) and the Btk motif (Sideras & Smith, 1995) . The critical tyrosine residue (Tyr527 in avian c-Src) which, when phosphorylated, inhibits Src catalytic activity by creating an intramolecular binding site for the Src SH2 domain, is not present at the C-termini of the Btk/Tec subfamily members (Pawson, 1997; Andreotti et al, 1997) . Instead, an intramolecular interaction between SH3 and TH domains has been suggested to restrict the access of SH3 region to potential substrates and therefore phosphorylation of tyrosine residue within the SH3 domain may disrupt the SH3-TH interaction and thereby allow the kinase to interact with its substrates (Andreotti et al, 1997; Park et al, 1996) .
As a tyrosine kinase, Btk was considered to be a potential oncogene (Vetrie et al, 1993) . It was reasonably anticipated that mutations that do not inactivate the kinase activity, but rather cause an enzymatic 'constitutively active' stage, could influence processes associated with malignant transformation. The isolation of a Btk mutant able to transform NIH-3T3 fibroblasts and to synergize with activated Src kinases (Li et al, 1995) was in accordance with the latter notion. Early studies for abnormal expression levels or mutations in the Btk locus in a collection of B-cell malignancies failed to reveal any association between Btk mutations and the development of B-cell acute lymphoblastic leukaemia (Katz et al, 1994) .
Btk is highly expressed in normal and malignant myeloid cell populations (Sideras & Smith, 1995; de Weers et al, 1993) ; however, its precise role in the development or function of this lineage is still unknown. Because of its expression in myeloid cells, its similarity to the Src family and its possible implication in malignant transformation, we have analysed the Btk sequences in myeloid malignancies, in order to evaluate the possible involvement of Btk mutations in the development or progression of these diseases. In 27 patients with AML (de novo or secondary) the structure of the Btk gene was analysed at the cDNA level, using the recently developed method that enables the rapid and convenient detection of mutations, namely the non-isotopic RNase cleavage assay (NIRCA) (Goldrick et al, 1996) . Six patients with XLA phenotype were also analysed for Btk mutations which, once characterized, served as positive controls in our studies. None of the AML patients had mutated Btk mRNA sequences. The only difference we were able to identify in three of our samples was a polymorphism at position 2031 that has been described previously (Katz et al, 1994) .
The absence of Btk mutations in our AML patients suggests that Btk mutations do not constitute a major element in the development of myeloid neoplasia.
MATERIALS AND METHODS
Patients. 27 patients with AML were analysed for the presence of Btk mutations. 11 patients were characterized as de novo AML and 16 patients as secondary AML. The patients with de novo AML were classified according to the FrenchAmerican-British (FAB) group as follows: M0 one patient, M1 two patients, M2 two patients, M3 two patients, M4 two patients and M5 two patients. 10 of the 16 patients with secondary AML suffered from myelodysplastic syndrome (MDS), whereas the remaining six were diagnosed as myeloid blast crisis of chronic myelogenous leukaemia (CML). More clinical and laboratory data from our 27 patients are presented in Table I .
Cells. Mononuclear cells from peripheral blood and bone marrow aspiration collected at the time of the diagnosis were separated by density gradient centrifugation. Cytochemistry and immunophenotypic analyses were carried out in bone marrow aspiration and peripheral blood. Total RNA from 2-4 × 10 7 mononuclear cells was extracted using a standard guanidium thiocyanate protocol (Chomczynski & Sacchi, 1987) . The final RNA pellet was re-dissolved in 30-50 ml TE buffer.
PCR. The central strategy of the procedure utilized was to generate appropriate templates by PCR for in-vitro transcription using the T7 and SP6 RNA polymerases. The approximate 2 kb of Btk coding region was separated into four fragments: PH, TS, SK and KIN (Fig 1B) . Every region was amplified by RT-PCR and a second nested PCR was also applied separately for every fragment. The sequences of T7 and SP6 RNA promoters constituted the 5 0 end of the sense and antisense nested primers respectively. Thus, the nested PCR products contained the T7 and SP6 phage promoters, and under suitable conditions using the corresponding polymerases, synthesis of microgram amounts of RNA was achieved with the PCR product as template. The positions and sequences of the utilized primers, designed with the aid of the Oligo-5 software (NBI, Plymouth, Min.) are shown in Fig 1 and Table II respectively. An overlap of about 200 bp or more between the four nested PCR products, was an essential criterion for the selection of the primers. For cDNA synthesis, approximately 1 mg (ϳ6-10 ml) re-dissolved RNA was reverse transcribed using 35 IU AMV reverse transcriptase in 20 ml reaction mixture (50 mM Tris-HCl, pH 8·0, 50 mM MgCl 2 , 0·5 mM spermidine and 10 mM DDT, 20 units RNAse inhibitor, 1 mM each deoxynucleotide triphosphate and 500 ng of oligodT primer) for 1 h at 42ЊC. 4 ml cDNA was used in 50 ml PCR reaction using 200 mM of each deoxynucleotide triphosphate, 60 pmol of each primer, 2·0 U Taq polymerase (Promega) in a PCR buffer supplied by the manufacturer. Thereafter, an appropriate amount of primary PCR product, usually 2-3 ml or less, was used for the nested PCR. Nested PCR was also carried out in a 50 ml reaction using the same concentrations as above. The conditions of primary PCR were: 2 min at 94ЊC followed by 30 cycles (94ЊC for 30 s, 55ЊC for 45 s, 72ЊC for 90 s) followed by 5 min at 72ЊC. Annealing at 59ЊC for 40 s was used to amplify the SK fragment. The conditions of nested PCR were: 2 min at 94ЊC followed by appropriate number of cycles (94ЊC for 30 s, 55ЊC for 45 s, 72ЊC for 90 s) followed by 5 min at 72ЊC after the last cycle. 25 cycles were used for the nested PCR amplification of the TS and SK fragments, whereas 20 cycles were optimal for the PH and KIN regions. All PCR amplifications were carried in the PCR-engine apparatus PTC-200, MJ Research (Watertown, Mass.). The PCR products were analysed in 1·5% agarose gels.
NIRCA (non-isotopic RNase cleavage assay).
This method is based on a previously described protocol (Goldrick et al, 1996) , and was performed using the MisMatch Detect II system (Ambion, Austin, Texas) with some modifications. As wild-type controls we used PCR products generated from either cloned cDNAs (Vetrie et al, 1993) or healthy individuals. The Btk mutations in six XLA patients were characterized by combining the NIRCA method and direct nucleotide sequencing. The PCR products derived from these individuals were thereafter utilized as positive controls.
In principle, a sense RNA product generated in vitro from a wild-type control template, using the appropriate RNA polymerase, was hybridized with the antisense RNA strand generated from either the same template (as a non-mutated control) and the template generated from AML patients or from XLA patients (as mutated positive control). To control the procedure, the opposite combination, i.e. hybridization using the antisense RNA strand of the wild-type sample with the sense strand generated from patient was performed. Sense and anti-sense RNA strands generated from each patient were also hybridized to each other as a second 'nonmutated' control. Thus, a group of four RNA duplexes was generated for every patient. Any mismatches in the RNA-RNA hybrids were revealed by RNase treatment and the Table III . Lanes 1 and 4: cleavage products of hybrids generated with sense and antisense RNA from the patient or the wild-type control template (reveal background cleavage products). Lanes 2 and 3: cleavage products of hybrids generated using sense RNA from the patient and antisense from the wild-type control, or antisense from the patient and sense from the wild-type control respectively (reveal mutation related to cleavage products). Lane 5: RNA duplex before RNase treatment. Lane 5*: nested PCR product from patient 3 that was shorter (deletion of exon 8, see Results and Discussion) than predictable size (see lane 6). Lane 6: nested PCR product used as template for the synthesis of RNA. Lane 7: 100 bp ladder molecular weight markers. separation of the products in 1·5% agarose gels. For every 10 ml transcription reaction 1-4 ml of nested PCR was used as template and transcription was carried out as suggested (Goldrick et al, 1996) , at 37ЊC for 90 min. Hybridization reactions were also performed according to manufacturer's instructions.
The RNase digestion step appears to be the most critical one for the successful utilization of the NIRCA method, and it is the step that requires careful optimization. Depending on which nucleotides would form the mismatches in the RNA hybrids, different RNases would cleave them more efficiently. Additionally, the optimal RNase dilutions greatly depend on the quantity of the RNA hybrids utilized in the reactions.
To determine the optimal cleavage conditions, we treated the generated RNA duplexes corresponding to the four overlapping fragments of Btk coding region, first with each of the three RNases separately, in dilutions 1/200 of RNase 1, 1/80 of RNase 2 and 1/150 of RNase 3. If cleavage products were easily seen with any of the single RNase treatments the analysis was terminated at this stage. In samples where ambiguous digestion products were seen, combinations of more than one RNase were utilized. For example, in some of the samples analysed with the KIN fragment, the combination of RNase 2 plus RNase 3 in dilutions 1/80 and 1/200, respectively, gave the best results, whereas in some of the samples the digestion with all three RNases together (no. 1, no. 2, no. 3), in dilutions 1/250, 1/50 and 1/150 respectively was applied in order to analyse the SK and TS regions. Even though this appears complicated, testing of different RNase combination was not very cumbersome and the optimal digestion conditions could easily be determined for each mutation. Once determined, the same conditions could be used for the diagnosis of the mutation in other members of the same family. The digestion reactions were performed according to the instructions of manufacturer. Cleavage products were analysed by electrophoresis in 1·5% agarose gels.
Sequencing. The results obtained by the NIRCA method were verified by directly sequencing (Sambrook et al, 1989) all the samples that appeared to be mutated and several of those that appeared to be normal. Nucleotide sequences were analysed using the GCG-version 8 sequence analysis program (GCG, Madison, Wis.).
RESULTS

NIRCA analysis can be used to identify Btk mutations at the mRNA level
Firstly, we determined the efficiency of this method by analysing and defining mutation in Btk genes of patients already diagnosed with XLA. We constructed probes that covered, with four overlapping regions, the entire coding sequences of the Btk gene (Fig 1, Table II ) and these were used to detect cleavage products, which were diagnostic for the presence of sequence alterations in several XLA samples. Six such samples were selected because the NIRCA analysis indicated that each of them contained nucleotide alterations The underlined sequences constitute the T7 and SP6 promoters.
* The numbers indicate the position of the most 5 0 nucleotide of the primer (numbering of cDNA according to Vetrie et al, 1993) .
within the four overlapping fragments of Btk coding region ( Fig 1C, Table III ). The potentially mutated as well as nonmutated areas from these patients were amplified by PCR, and their nucleotide sequence was determined. As expected, the direct nucleotide sequence analysis confirmed the NIRCA results and demonstrated the presence of the alteration shown in Table III , located at positions compatible with those predicted from the size of the cleavage products (Table III) . The coding regions that did not appear to have mutations in the NIRCA analysis were found to carry wild-type sequences, as expected. The six XLA patients thus provided the crucial positive control samples for our study. The mutations found in patients 1 (deletion 1598-1601), 3 (deletion exon 8), 4 (insertion G at position 1356) and 5 (deletion 1420-1421) (Table III) are new and do not appear in the Btk mutation database (http://www.helsinki.fi/science/signal/btkbase.html). Mutations similar to the ones found in patients 2 (G1913A) and 6 (C169T) (Table III) have been already submitted in the database under accession codes A0080 and A0105, respectively. Collectively, the above data demonstrated that NIRCA is a reliable, easy and rapid method for screening for the sequence alteration of Btk gene at the mRNA level.
Absence of Btk mutations in patients with AML.
Having demonstrated the validity of the NIRCA assay, we initiated the analysis of leukaemic samples. The Table III (Vetrie et al, 1993) . Patients 8A, 8B and 8C are three patients with myeloid malignancy (patients 3, 12 and 22 in Table I ). The above samples were selected to function as positive controls in our studies. The four overlapping regions, i.e. KIN, TS, SK and PH, are described in Fig 1 and in Materials and Methods.
* The length of cleavage products was determined in ethidium bromide stained agarose gels. † The size of the cleavage products indicated the position of the mutations relative to one or the other end of the target region. Therefore two putative positions were considered initially.
‡ The precise position and nature of the mutations was identified by direct sequencing analysis. characteristics of the different samples, i.e. their FAB classification, immunophenotype, the presence of N-ras mutations (two AML and two MDS patients) and the presence of the BCR/ABL rearrangements in six CML patients, are summarized in Table I . The only alteration that we were able to detect in three of our patients was a C → T polymorphism at position 2031 (Fig 2) . The same polymorphism has been reported in 4/23 B-ALL patients (Katz et al, 1994) . To validate further the NIRCA analysis, the sequences of the entire Btk message were determined in several neoplastic samples. These analyses failed to reveal any further mutations.
DISCUSSION
Cytoplasmic PTKs are thought to play important roles in several cellular signalling pathways that regulate cell proliferation and differentiation (Bolen, 1993) . They function as central switching mechanisms by catalysing the phosphorylation of tyrosine residues in specific target proteins. Because of their role in cellular development, genes encoding proteins with tyrosine kinase activity form a large proportion of known proto-oncogenes (Cantley et al, 1991) .
In the last few years many genetic events that may be involved in the pathogenesis of leukaemia have been recognized (Caligiuri et al, 1997; Drexler et al, 1995; Nichols & Nimer, 1992) . Tyrosine kinase deregulation has been identified as playing a critical role in the development of some myeloid malignancies, as in the case of BCR/ABL rearrangement in the development of CML (Hughes & Goldman, 1995) . Btk is a protein tyrosine kinase that is highly expressed in myeloid cells (Sideras & Smith, 1995; de Weers et al, 1993) .
Mutation in the Btk PH domain was shown to transform NIH-3T3 cells and to synergize with the transforming activity of Src kinases (Li et al, 1995) . We hypothesized that mutations that increased Btk enzymatic activity could constitute a co-factor in the development of myeloid neoplasia. To investigate this possibility, we selected a number of samples from patients with either de-novo AML, or MDS and CML cases in blastic transformation and myeloid blast crisis respectively and searched for mutations in the coding regions of their Btk genes using the recently developed method NIRCA. Despite the fact that the number of patients in the current study was relatively small and heterogenous, nevertheless our analysis is more compatible with the notion that mutations in the Btk gene do not constitute a major co-factor in the development of myeloid neoplasia.
Our analysis performed by NIRCA in AML and XLA patients established an absolute accordance between RNase cleavage and sequencing data, thus illustrating the value of NIRCA as a first-step method for screening of XLA patients. The detection rate in our studies was as high as that described in the original description of the NIRCA in the factor IX model system (Goldrick et al, 1996) .
More has been learned recently about the putative function of Btk. A possible interplay between Btk and the apoptosis regulating molecular cascades has been obtained in different systems. For example, Btk was found to be essential for the ionizing radiation-induced apoptosis in the chicken cell line DT-40 (Uckun et al, 1996) . In contrast, Btk was found to be essential for prolonged survival in vitro and in vivo of primary unstimulated B cells (Kawakami et al, 1997; Anderson et al, 1996; Woodland et al, 1996) . It is therefore slowly becoming clear that, in addition to whatever role Btk might play upon activation, it probably plays an essential role earlier in haemostasis, probably by increasing cell survival in the absence of an antigenic stimulation. If this notion is correct, then other types of neoplasia could be likely candidates for harbouring a deregulated Btk function. For example, B-cell chronic lymphocytic leukaemia (B-CLL) is likely to be investigated in the close future. The NIRCA system we have reported here for the analysis of Btk mutations will dramatically facilitate such studies.
